DE68928405D1 - Endmarkierte Nukleotid-Sonde - Google Patents

Endmarkierte Nukleotid-Sonde

Info

Publication number: DE68928405D1
Authority: DE; Germany
Prior art keywords: labeled nucleotide; nucleotide probe; probe; labeled; nucleotide
Prior art date: 1988-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE68928405T

Other languages

English (en)

Other versions

DE68928405T2 (de

Inventor

Christine L Brakel

Alan F Cook

Edmund Vuocolo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Enzo Biochem Inc

Original Assignee

Enzo Biochem Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-26

Filing date

1989-02-24

Publication date

1997-12-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22577585&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68928405(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-02-24 Application filed by Enzo Biochem Inc filed Critical Enzo Biochem Inc

1997-12-04 Application granted granted Critical

1997-12-04 Publication of DE68928405D1 publication Critical patent/DE68928405D1/de

1998-06-18 Publication of DE68928405T2 publication Critical patent/DE68928405T2/de

2009-02-25 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

DE68928405T 1988-02-26 1989-02-24 Endmarkierte Nukleotid-Sonde Expired - Lifetime DE68928405T2 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/160,607 US5082830A (en)	1988-02-26	1988-02-26	End labeled nucleotide probe

Publications (2)

Publication Number	Publication Date
DE68928405D1 true DE68928405D1 (de)	1997-12-04
DE68928405T2 DE68928405T2 (de)	1998-06-18

Family

ID=22577585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE68928405T Expired - Lifetime DE68928405T2 (de)	1988-02-26	1989-02-24	Endmarkierte Nukleotid-Sonde

Country Status (5)

Country	Link
US (1)	US5082830A (de)
EP (2)	EP0330221B1 (de)
JP (1)	JP3083297B2 (de)
CA (1)	CA1335961C (de)
DE (1)	DE68928405T2 (de)

Families Citing this family (659)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4948882A (en) *	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5242794A (en) *	1984-12-13	1993-09-07	Applied Biosystems, Inc.	Detection of specific sequences in nucleic acids
US6346413B1 (en)	1989-06-07	2002-02-12	Affymetrix, Inc.	Polymer arrays
US6919211B1 (en) *	1989-06-07	2005-07-19	Affymetrix, Inc.	Polypeptide arrays
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en)	1989-06-07	1998-09-01	Fodor; Stephen P.A.	Method of detecting nucleic acids
US5925525A (en) *	1989-06-07	1999-07-20	Affymetrix, Inc.	Method of identifying nucleotide differences
US5744101A (en) *	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US6040138A (en) *	1995-09-15	2000-03-21	Affymetrix, Inc.	Expression monitoring by hybridization to high density oligonucleotide arrays
US5424186A (en)	1989-06-07	1995-06-13	Affymax Technologies N.V.	Very large scale immobilized polymer synthesis
US6309822B1 (en)	1989-06-07	2001-10-30	Affymetrix, Inc.	Method for comparing copy number of nucleic acid sequences
US6406844B1 (en)	1989-06-07	2002-06-18	Affymetrix, Inc.	Very large scale immobilized polymer synthesis
US6955915B2 (en) *	1989-06-07	2005-10-18	Affymetrix, Inc.	Apparatus comprising polymers
US6379895B1 (en)	1989-06-07	2002-04-30	Affymetrix, Inc.	Photolithographic and other means for manufacturing arrays
US6551784B2 (en)	1989-06-07	2003-04-22	Affymetrix Inc	Method of comparing nucleic acid sequences
US6506558B1 (en)	1990-03-07	2003-01-14	Affymetrix Inc.	Very large scale immobilized polymer synthesis
US5210015A (en)	1990-08-06	1993-05-11	Hoffman-La Roche Inc.	Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1992010588A1 (en)	1990-12-06	1992-06-25	Affymax Technologies N.V.	Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US5290925A (en) *	1990-12-20	1994-03-01	Abbott Laboratories	Methods, kits, and reactive supports for 3' labeling of oligonucleotides
DE4123540A1 (de) *	1991-07-16	1993-01-21	Boehringer Mannheim Gmbh	Immobilisierung von nukleinsaeuren
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
WO1993010140A1 (en) *	1991-11-21	1993-05-27	Pharmagenics, Inc.	Oligonucleotides having modified anionic moieties
US6943034B1 (en) *	1991-11-22	2005-09-13	Affymetrix, Inc.	Combinatorial strategies for polymer synthesis
US6849462B1 (en)	1991-11-22	2005-02-01	Affymetrix, Inc.	Combinatorial strategies for polymer synthesis
EP0972564B1 (de) *	1991-11-22	2003-05-28	Affymetrix, Inc. (a Delaware Corporation)	Verfahren zur Herstellung von Polymerarrays
US6468740B1 (en)	1992-11-05	2002-10-22	Affymetrix, Inc.	Cyclic and substituted immobilized molecular synthesis
IL107150A0 (en) *	1992-09-29	1993-12-28	Isis Pharmaceuticals Inc	Oligonucleotides having a conserved g4 core sequence
US5482698A (en) *	1993-04-22	1996-01-09	Immunomedics, Inc.	Detection and therapy of lesions with biotin/avidin polymer conjugates
ATE247128T1 (de)	1993-09-03	2003-08-15	Isis Pharmaceuticals Inc	Aminoderivatisierte nukleoside und oligonukleoside
US5925517A (en) *	1993-11-12	1999-07-20	The Public Health Research Institute Of The City Of New York, Inc.	Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5446137B1 (en) *	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5824473A (en)	1993-12-10	1998-10-20	California Institute Of Technology	Nucleic acid mediated electron transfer
US5952172A (en)	1993-12-10	1999-09-14	California Institute Of Technology	Nucleic acid mediated electron transfer
US6071699A (en) *	1996-06-07	2000-06-06	California Institute Of Technology	Nucleic acid mediated electron transfer
US5591578A (en) *	1993-12-10	1997-01-07	California Institute Of Technology	Nucleic acid mediated electron transfer
US7323298B1 (en)	1994-06-17	2008-01-29	The Board Of Trustees Of The Leland Stanford Junior University	Microarray for determining the relative abundances of polynuceotide sequences
US7378236B1 (en)	1994-06-17	2008-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Method for analyzing gene expression patterns
US5620850A (en)	1994-09-26	1997-04-15	President And Fellows Of Harvard College	Molecular recognition at surfaces derivatized with self-assembled monolayers
US8236493B2 (en) *	1994-10-21	2012-08-07	Affymetrix, Inc.	Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
EP0880598A4 (de) *	1996-01-23	2005-02-23	Affymetrix Inc	Verfahren zur analyse von nukleinsäure
JP3898228B2 (ja) *	1996-04-12	2007-03-28	ザパブリックヘルスリサーチインスティチュートオブザシティーオブニューヨークインク	検出プローブ、キット及びアッセイ
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20040203024A1 (en) *	1996-06-06	2004-10-14	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US7812149B2 (en) *	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040147022A1 (en) *	1996-06-06	2004-07-29	Baker Brenda F.	2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20050042647A1 (en) *	1996-06-06	2005-02-24	Baker Brenda F.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US20040266706A1 (en) *	2002-11-05	2004-12-30	Muthiah Manoharan	Cross-linked oligomeric compounds and their use in gene modulation
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050053976A1 (en) *	1996-06-06	2005-03-10	Baker Brenda F.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US20030044941A1 (en)	1996-06-06	2003-03-06	Crooke Stanley T.	Human RNase III and compositions and uses thereof
US6444423B1 (en)	1996-06-07	2002-09-03	Molecular Dynamics, Inc.	Nucleosides comprising polydentate ligands
US7045285B1 (en) *	1996-11-05	2006-05-16	Clinical Micro Sensors, Inc.	Electronic transfer moieties attached to peptide nucleic acids
US7381525B1 (en)	1997-03-07	2008-06-03	Clinical Micro Sensors, Inc.	AC/DC voltage apparatus for detection of nucleic acids
US7160678B1 (en)	1996-11-05	2007-01-09	Clinical Micro Sensors, Inc.	Compositions for the electronic detection of analytes utilizing monolayers
US7393645B2 (en) *	1996-11-05	2008-07-01	Clinical Micro Sensors, Inc.	Compositions for the electronic detection of analytes utilizing monolayers
US7014992B1 (en) *	1996-11-05	2006-03-21	Clinical Micro Sensors, Inc.	Conductive oligomers attached to electrodes and nucleoside analogs
US6096273A (en) *	1996-11-05	2000-08-01	Clinical Micro Sensors	Electrodes linked via conductive oligomers to nucleic acids
US6013459A (en) *	1997-06-12	2000-01-11	Clinical Micro Sensors, Inc.	Detection of analytes using reorganization energy
CA2294988C (en)	1997-07-01	2015-11-24	Isis Pharmaceuticals Inc.	Compositions and methods for the delivery of oligonucleotides via the alimentary canal
CA2313641A1 (en) *	1997-12-12	1999-06-24	Digene Corporation	Universal collection medium
US6686150B1 (en)	1998-01-27	2004-02-03	Clinical Micro Sensors, Inc.	Amplification of nucleic acids with electronic detection
JP2002500897A (ja)	1998-01-27	2002-01-15	クリニカル・マイクロ・センサーズ・インコーポレイテッド	電子的核酸検出の増幅
US6004755A (en) *	1998-04-07	1999-12-21	Incyte Pharmaceuticals, Inc.	Quantitative microarray hybridizaton assays
US20040186071A1 (en)	1998-04-13	2004-09-23	Bennett C. Frank	Antisense modulation of CD40 expression
US7321828B2 (en) *	1998-04-13	2008-01-22	Isis Pharmaceuticals, Inc.	System of components for preparing oligonucleotides
EP1080103A4 (de) *	1998-05-21	2003-07-02	Isis Pharmaceuticals Inc	Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
AU753270B2 (en) *	1998-05-21	2002-10-10	Isis Pharmaceuticals, Inc.	Compositions and methods for topical delivery of oligonucleotides
US6290839B1 (en)	1998-06-23	2001-09-18	Clinical Micro Sensors, Inc.	Systems for electrophoretic transport and detection of analytes
US7087148B1 (en)	1998-06-23	2006-08-08	Clinical Micro Sensors, Inc.	Binding acceleration techniques for the detection of analytes
US6761816B1 (en)	1998-06-23	2004-07-13	Clinical Micro Systems, Inc.	Printed circuit boards with monolayers and capture ligands
US6037130A (en) *	1998-07-28	2000-03-14	The Public Health Institute Of The City Of New York, Inc.	Wavelength-shifting probes and primers and their use in assays and kits
US6225293B1 (en)	1998-09-02	2001-05-01	Isis Pharmaceuticals, Inc.	Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6740518B1 (en)	1998-09-17	2004-05-25	Clinical Micro Sensors, Inc.	Signal detection techniques for the detection of analytes
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
AU1241000A (en)	1998-10-27	2000-05-15	Clinical Micro Sensors, Inc.	Detection of target analytes using particles and electrodes
US6545264B1 (en)	1998-10-30	2003-04-08	Affymetrix, Inc.	Systems and methods for high performance scanning
WO2001027261A2 (en) *	1998-11-11	2001-04-19	Pantheco A/S	Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino
US6833267B1 (en) *	1998-12-30	2004-12-21	Clinical Micro Sensors, Inc.	Tissue collection devices containing biosensors
US6300320B1 (en)	1999-01-05	2001-10-09	Isis Pharmaceuticals, Inc.	Modulation of c-jun using inhibitors of protein kinase C
US6127124A (en) *	1999-01-20	2000-10-03	Isis Pharmaceuticals, Inc.	Fluorescence based nuclease assay
US7098192B2 (en)	1999-04-08	2006-08-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of STAT3 expression
US20020177135A1 (en) *	1999-07-27	2002-11-28	Doung Hau H.	Devices and methods for biochip multiplexing
US7312087B2 (en)	2000-01-11	2007-12-25	Clinical Micro Sensors, Inc.	Devices and methods for biochip multiplexing
US6942771B1 (en) *	1999-04-21	2005-09-13	Clinical Micro Sensors, Inc.	Microfluidic systems in the electrochemical detection of target analytes
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
AU779220B2 (en)	1999-07-26	2005-01-13	Clinical Micro Sensors, Inc.	Sequence determination of nucleic acids using electronic detection
US6613516B1 (en) *	1999-10-30	2003-09-02	Affymetrix, Inc.	Preparation of nucleic acid samples
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
US20030176385A1 (en) *	2000-02-15	2003-09-18	Jingfang Ju	Antisense modulation of protein expression
FR2805545B1 (fr) *	2000-02-24	2002-05-17	Argene Sa	Procede electrochimique de detection d'acides nucleiques
US6680172B1 (en)	2000-05-16	2004-01-20	Regents Of The University Of Michigan	Treatments and markers for cancers of the central nervous system
US7601497B2 (en)	2000-06-15	2009-10-13	Qiagen Gaithersburg, Inc.	Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) *	2000-06-15	2008-10-21	Digene Corporation	Detection of nucleic acids by type-specific hybrid capture method
JP4382265B2 (ja) *	2000-07-12	2009-12-09	日本電気株式会社	酸化シリコン膜の形成方法及びその形成装置
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU2001296846B2 (en)	2000-10-12	2007-07-05	University Of Rochester	Compositions that inhibit proliferation of cancer cells
US7767802B2 (en)	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
FI115139B (fi) *	2001-01-10	2005-03-15	Valtion Teknillinen	Menetelmä ja testipakkaus solu- tai kudosnäytteissä olevien polynukleotidien määrässä tapahtuvien vaihteluiden kvantitatiiviseen ja/tai vertailevaan arvioimiseen
EP1377683A4 (de) *	2001-04-11	2004-09-08	Us Gov Health & Human Serv	Modifizierte zufallsprimer zur sondenmarkierung
JP2004537516A (ja)	2001-05-11	2004-12-16	オラセンスリミテッド	アンチセンス浸透促進剤
SE0101934D0 (sv) *	2001-06-01	2001-06-01	Pharmacia Ab	New methods
US7803915B2 (en) *	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
MXPA03011985A (es)	2001-06-20	2004-03-26	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores.
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US6974671B1 (en)	2001-09-12	2005-12-13	Salk Institute For Biological Studies	Methods for indentifying compounds that modulate gluconeogenesis through the binding of CREB to the PGC-1 promoter
KR101008758B1 (ko)	2001-09-18	2011-01-14	제넨테크, 인크.	종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
AU2002334895B2 (en)	2001-10-09	2006-10-19	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
EP2067472A1 (de)	2002-01-02	2009-06-10	Genentech, Inc.	Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20030180712A1 (en)	2002-03-20	2003-09-25	Biostratum Ab	Inhibition of the beta3 subunit of L-type Ca2+ channels
NZ535925A (en)	2002-04-16	2008-06-30	Genentech Inc	An isolated antibody that binds to a particular polypeptide
AU2003279697A1 (en) *	2002-05-17	2004-02-16	Nugen Technologies, Inc.	Methods for fragmentation, labeling and immobilizaton of nucleic acids
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
WO2003105780A2 (en) *	2002-06-18	2003-12-24	Epigenesis Pharmaceuticals, Inc.	A dry powder oligonucleotide formulation, preparation and its uses
FI20021325A0 (fi) *	2002-07-05	2002-07-05	Valtion Teknillinen	Menetelmä ja reagenssipakkaus yksittäisten polynukleotidien määrän määrittämiseksi
US20040019000A1 (en) *	2002-07-19	2004-01-29	Muthiah Manoharan	Polyalkyleneamine-containing oligomers
WO2004013160A2 (en)	2002-08-05	2004-02-12	University Of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US6878805B2 (en) *	2002-08-16	2005-04-12	Isis Pharmaceuticals, Inc.	Peptide-conjugated oligomeric compounds
CN1694959B (zh)	2002-09-13	2013-09-18	雷普利瑟公司	非序列互补的抗病毒寡核苷酸
WO2004031350A2 (en)	2002-09-26	2004-04-15	Amgen, Inc.	Modulation of forkhead box o1a expression
JP2006515318A (ja) *	2002-10-29	2006-05-25	ファルマシア・コーポレーション	特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
EP1578765A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Oligomere verbindungen,die zuckerersatzstoffe enthalten, und zusammensetzung zur verwendung in dergenmodulation
EP1560839A4 (de)	2002-11-05	2008-04-23	Isis Pharmaceuticals Inc	Chimäre oligomere verbindungen und derenverwendung in der genmodulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003294281B2 (en)	2002-11-13	2010-05-20	Kastle Therapeutics, Llc	Antisense modulation of apolipoprotein B expression
SI2336318T1 (sl)	2002-11-13	2013-07-31	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
WO2004045520A2 (en)	2002-11-15	2004-06-03	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
WO2004046330A2 (en)	2002-11-15	2004-06-03	Morphotek, Inc.	Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
AU2003294462C1 (en)	2002-11-21	2011-06-30	University Of Utah Research Foundation	Purinergic modulation of smell
US7144999B2 (en)	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
US7468356B2 (en)	2003-02-11	2008-12-23	Antisense Therapeutics Ltd.	Modulation of insulin like growth factor I receptor expression
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en)	2003-03-21	2004-09-23	Isis Pharmaceuticals Inc.	Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US7399853B2 (en)	2003-04-28	2008-07-15	Isis Pharmaceuticals	Modulation of glucagon receptor expression
CA2540692C (en) *	2003-06-02	2013-05-28	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
BRPI0410886A (pt)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
US7786290B2 (en)	2003-06-13	2010-08-31	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
EP1636342A4 (de) *	2003-06-20	2008-10-08	Isis Pharmaceuticals Inc	Oligomere verbindungen zur verwendung bei der modulation von genen
US7790691B2 (en) *	2003-06-20	2010-09-07	Isis Pharmaceuticals, Inc.	Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
EP1648914A4 (de)	2003-07-31	2009-12-16	Regulus Therapeutics Inc	Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) *	2003-09-11	2007-05-31	Replicor Inc.	Oligonucleotides targeting prion diseases
AU2004274942B2 (en)	2003-09-18	2008-02-28	Isis Pharmaceuticals, Inc.	Modulation of eIF4E expression
CA2538252C (en) *	2003-09-18	2014-02-25	Isis Pharmaceuticals, Inc.	4'-thionucleosides and oligomeric compounds
CN1882602B (zh)	2003-10-10	2011-02-09	阿尔卡米亚肿瘤股份有限公司	在疾病治疗中乙酰透明质酸合成的调节和降解
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
EP2161283B1 (de)	2003-11-17	2014-06-04	Genentech, Inc.	Zusammensetzungen, die Antikörper gegen CD79b enthalten, die an Wachstumshemmer oder an zytotoxische Subtanzen gekoppelt sind und Verfahren zur Behandlung von Tumoren hämatopoetischen Ursprungs
US20050208538A1 (en)	2003-12-29	2005-09-22	Nurith Kurn	Methods for analysis of nucleic acid methylation status and methods for fragmentation, labeling and immobilization of nucleic acids
WO2005071080A2 (en)	2004-01-20	2005-08-04	Isis Pharmaceuticals, Inc.	Modulation of glucocorticoid receptor expression
US7468431B2 (en) *	2004-01-22	2008-12-23	Isis Pharmaceuticals, Inc.	Modulation of eIF4E-BP2 expression
US8569474B2 (en) *	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en)	2004-03-15	2005-09-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of rna by rnase h
AU2005230684B2 (en)	2004-04-05	2011-10-06	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) *	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050260755A1 (en) *	2004-04-06	2005-11-24	Isis Pharmaceuticals, Inc.	Sequential delivery of oligomeric compounds
JP4584987B2 (ja)	2004-04-30	2010-11-24	アルニラムファーマスーティカルズインコーポレイテッド	Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
CA2564251C (en)	2004-05-21	2018-04-10	The Uab Research Foundation	Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
US8394947B2 (en) *	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
EP1766052A4 (de) *	2004-06-03	2009-12-16	Isis Pharmaceuticals Inc	Chimärische oligomere zusammensetzungen mit gap
WO2005121372A2 (en) *	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US7620402B2 (en) *	2004-07-09	2009-11-17	Itis Uk Limited	System and method for geographically locating a mobile device
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) *	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006032144A1 (en)	2004-09-23	2006-03-30	Arc Pharmaceuticals, Inc.	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
BRPI0607985A2 (pt)	2005-03-10	2009-10-27	Genentech Inc	modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
US7476733B2 (en) *	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP2298829B1 (de)	2005-05-31	2017-09-20	École Polytechnique Fédérale de Lausanne (EPFL)	Triblock-Copolymere zur zytoplasmischen Verabreichung gen-basierter Arzneimittel
WO2006138145A1 (en)	2005-06-14	2006-12-28	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
CA2625891A1 (en)	2005-10-14	2007-04-26	Carlton D. Donald	Inhibition of pax2 by defb1 induction as a therapy for cancer
EP1941059A4 (de)	2005-10-28	2010-11-03	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur hemmung der expression des huntingtin-gens
US20100069461A1 (en)	2005-11-09	2010-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
EP1966377A2 (de)	2005-11-21	2008-09-10	Isis Pharmaceuticals, Inc.	Modulation der eif4e-bp2-expression
NZ587704A (en)	2006-03-31	2012-04-27	Alnylam Pharmaceuticals Inc	Use of dsRNA for inhibiting expression of Eg5 gene
EP2013344B1 (de) *	2006-05-03	2012-08-29	Baltic Technology Development, Ltd.	Antisense-agentien mit kombination von mit stark gebundener base modifiziertem oligonukleotid und künstlicher nuklease
US7812150B2 (en)	2006-05-19	2010-10-12	Alnylam Pharmaceuticals, Inc.	RNAi modulation of Aha and therapeutic uses thereof
CA2653451C (en)	2006-05-22	2015-12-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of ikk-b gene
US20090209625A1 (en) *	2006-05-23	2009-08-20	Sanjay Bhanot	Modulation of chrebp expression
EP2029775B1 (de) *	2006-06-05	2014-10-15	California Institute Of Technology	Echtzeit-mikroarrays
US11001881B2 (en)	2006-08-24	2021-05-11	California Institute Of Technology	Methods for detecting analytes
US20090280188A1 (en) *	2006-06-23	2009-11-12	Northwestern University	Asymmetric functionalizated nanoparticles and methods of use
CA2656315A1 (en) *	2006-06-30	2008-01-10	Nugen Technologies, Inc.	Methods for fragmentation and labeling of nucleic acids
US8198253B2 (en)	2006-07-19	2012-06-12	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to HBXIP
US11525156B2 (en)	2006-07-28	2022-12-13	California Institute Of Technology	Multiplex Q-PCR arrays
WO2008014485A2 (en)	2006-07-28	2008-01-31	California Institute Of Technology	Multiplex q-pcr arrays
US11560588B2 (en)	2006-08-24	2023-01-24	California Institute Of Technology	Multiplex Q-PCR arrays
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
KR20090089462A (ko)	2006-12-11	2009-08-21	유니버시티 오브 유타 리써치 파운데이션	병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
MX2009008470A (es)	2007-02-09	2009-11-26	Univ Northwestern	Particulas para detectar objetivos intracelulares.
AU2008232891B2 (en)	2007-03-29	2012-01-12	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the Ebola
CA2689923A1 (en)	2007-05-30	2008-12-11	Northwestern University	Nucleic acid functionalized nanoparticles for therapeutic applications
US20090215643A1 (en)	2007-07-26	2009-08-27	Cellay, Llc	Highly Visible Chromosome-Specific Probes and Related Methods
EP2195331B1 (de) *	2007-08-28	2013-11-20	Uab Research Foundation	Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
CA2697957A1 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009039466A1 (en)	2007-09-20	2009-03-26	Vanderbilt University	Free solution measurement of molecular interactions by backscattering interferometry
US7951785B2 (en) *	2007-09-21	2011-05-31	California Institute Of Technology	NFIA in glial fate determination, glioma therapy and astrocytoma treatment
MX2010003465A (es)	2007-10-02	2010-07-05	Amgen Inc	Incremento de eritropoyetina utilizando acidos nucleicos que hibridan para micro-arn y precursores de los mismos.
MX2010004984A (es) *	2007-11-05	2010-07-29	Baltic Technology Dev Ltd	Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos.
WO2009067243A2 (en)	2007-11-20	2009-05-28	Isis Pharmaceuticals Inc.	Modulation of cd40 expression
WO2009070742A2 (en)	2007-11-28	2009-06-04	Great Basin Scientific	Methods and compositions for signal enhancement using multivalent interactions
EP2245159A2 (de)	2007-12-10	2010-11-03	Alnylam Pharmaceuticals Inc.	Zusammensetzungen und verfahren zur hemmung der expression des faktor-vii-gens
EP2712926A2 (de)	2008-03-05	2014-04-02	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5- und des VEGF-Gens
EP2105145A1 (de) *	2008-03-27	2009-09-30	ETH Zürich	Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
WO2009124295A2 (en) *	2008-04-04	2009-10-08	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
CA2721183C (en)	2008-04-11	2019-07-16	Alnylam Pharmaceuticals, Inc.	Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US8324366B2 (en)	2008-04-29	2012-12-04	Alnylam Pharmaceuticals, Inc.	Compositions and methods for delivering RNAI using lipoproteins
WO2010017509A1 (en) *	2008-08-07	2010-02-11	Isis Pharmaceuticals, Inc.	Modulation of transthyretin expression for the treatment of cns related disorders
NZ601660A (en)	2008-08-25	2014-05-30	Excaliard Pharmaceuticals Inc	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3208337A1 (de)	2008-09-02	2017-08-23	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
WO2010039548A2 (en)	2008-09-23	2010-04-08	Alnylam Pharmaceuticals, Inc.	Chemical modifications of monomers and oligonucleotides with cycloaddition
EP3109321B1 (de)	2008-09-25	2019-05-01	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
KR20160079921A (ko)	2008-10-20	2016-07-06	알닐람 파마슈티칼스 인코포레이티드	트랜스티레틴의 발현을 억제하기 위한 조성물 및 방법
US8987435B2 (en)	2008-10-24	2015-03-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
JP2012506705A (ja) *	2008-10-27	2012-03-22	キアジェンゲイサーズバーグインコーポレイテッド	迅速に結果を得るハイブリッドキャプチャー法による分析およびシステム
CN105152939A (zh)	2008-11-10	2015-12-16	阿尔尼拉姆医药品有限公司	用于递送治疗剂的脂质和组合物
WO2010060110A1 (en) *	2008-11-24	2010-05-27	Northwestern University	Polyvalent rna-nanoparticle compositions
JP6091752B2 (ja)	2008-12-04	2017-03-08	クルナ・インコーポレーテッド	Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
RU2618688C2 (ru)	2008-12-04	2017-05-10	КьюРНА,Инк.,US	Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
EP2370580B1 (de)	2008-12-04	2019-09-11	CuRNA, Inc.	Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
EP2373382B1 (de)	2008-12-10	2017-02-15	Alnylam Pharmaceuticals, Inc.	Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
US20100233270A1 (en) *	2009-01-08	2010-09-16	Northwestern University	Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010203474B2 (en) *	2009-01-08	2015-11-19	Northwestern University	Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
AU2010208311B2 (en) *	2009-01-28	2016-07-07	Qiagen Gaithersburg, Inc.	Sequence-specific large volume sample preparation method and assay
WO2010091308A2 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
HUE026280T2 (en)	2009-02-12	2016-06-28	Curna Inc	Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
US20110319476A1 (en)	2009-02-12	2011-12-29	Opko Curna, Llc	Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010099341A1 (en)	2009-02-26	2010-09-02	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of mig-12 gene
EP2403863B1 (de)	2009-03-02	2013-08-28	Alnylam Pharmaceuticals Inc.	Chemische modifikationen von nukleinsäure
US20110319317A1 (en)	2009-03-04	2011-12-29	Opko Curna, Llc	Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
WO2010105209A1 (en)	2009-03-12	2010-09-16	Alnylam Pharmaceuticals, Inc.	LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
US9464287B2 (en)	2009-03-16	2016-10-11	Curna, Inc.	Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
US9708604B2 (en)	2009-03-17	2017-07-18	Curna, Inc.	Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
EP3248618A1 (de)	2009-04-22	2017-11-29	Massachusetts Institute Of Technology	Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
JP5738278B2 (ja) *	2009-05-01	2015-06-24	キアジェンゲイサーズバーグインコーポレイテッド	試料中のｒｎａスプライシング形態を検出するための非標的増幅法
US8318690B2 (en)	2009-05-01	2012-11-27	Curna, Inc.	Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
CA2761152A1 (en)	2009-05-06	2010-11-11	Opko Curna, Llc	Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
CN102803492B (zh)	2009-05-06	2016-06-29	库尔纳公司	通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
US8957037B2 (en)	2009-05-18	2015-02-17	Curna, Inc.	Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
JP2012527248A (ja)	2009-05-22	2012-11-08	クルナ・インコーポレーテッド	転写因子ｅ３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるｔｆｅ３およびインスリン受容体基質２（ｉｒｓ２）関連疾患の処置
KR101704988B1 (ko)	2009-05-28	2017-02-08	큐알엔에이, 인크.	항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
SG10201912450XA (en)	2009-06-10	2020-03-30	Arbutus Biopharma Corp	Improved lipid formulation
EP2443237B1 (de)	2009-06-16	2017-02-22	CuRNA, Inc.	Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
KR101702689B1 (ko)	2009-06-16	2017-02-06	큐알엔에이, 인크.	Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
PL3305302T3 (pl)	2009-06-17	2019-02-28	Biogen Ma Inc.	Kompozycje i sposoby modulacji składania smn2 u pacjenta
CN102597238B (zh)	2009-06-24	2016-06-29	库尔纳公司	通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
CN102482672B (zh)	2009-06-26	2016-11-09	库尔纳公司	通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
EP2462229B1 (de)	2009-08-05	2016-05-11	CuRNA, Inc.	Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
EP2810643A3 (de)	2009-08-14	2015-03-11	Alnylam Pharmaceuticals Inc.	Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus
US9023822B2 (en)	2009-08-25	2015-05-05	Curna, Inc.	Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
DK2473522T3 (en)	2009-09-02	2016-11-28	Genentech Inc	Smoothened MUTANT AND METHODS OF USING THE SAME
WO2011032124A1 (en)	2009-09-14	2011-03-17	Qiagen Gaithersburg, Inc.	Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media
WO2011050194A1 (en)	2009-10-22	2011-04-28	Genentech, Inc.	Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
JP5866119B2 (ja)	2009-10-30	2016-02-17	ノースウェスタンユニバーシティ	鋳型ナノ複合体
CA2781887C (en)	2009-11-30	2018-03-27	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP2509636B1 (de)	2009-12-07	2017-07-19	Arbutus Biopharma Corporation	Zusammensetzungen für nukleinsäurefreisetzung
KR101823702B1 (ko)	2009-12-16	2018-01-30	큐알엔에이, 인크.	막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
WO2011075656A1 (en)	2009-12-18	2011-06-23	The University Of British Columbia	Methods and compositions for delivery of nucleic acids
KR101793753B1 (ko)	2009-12-23	2017-11-03	큐알엔에이, 인크.	커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
DK2516648T3 (en)	2009-12-23	2018-02-12	Curna Inc	TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
KR101838305B1 (ko)	2009-12-29	2018-03-13	큐알엔에이, 인크.	ＮＲＦ1(ＮｕｃｌｅａｒＲｅｓｐｉｒａｔｏｒｙＦａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CN102770540B (zh)	2009-12-29	2017-06-23	库尔纳公司	通过抑制肿瘤蛋白63(p63)的天然反义转录物而治疗p63相关疾病
RU2611187C2 (ru)	2010-01-04	2017-02-21	Курна, Инк.	Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8
CA2786056C (en)	2010-01-06	2023-03-14	Curna, Inc.	Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
DK2524039T3 (en)	2010-01-11	2018-03-12	Curna Inc	TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
US8946182B2 (en)	2010-01-25	2015-02-03	Curna, Inc.	Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
US9198972B2 (en)	2010-01-28	2015-12-01	Alnylam Pharmaceuticals, Inc.	Monomers and oligonucleotides comprising cycloaddition adduct(s)
EP2529031B1 (de)	2010-01-29	2014-07-09	QIAGEN Gaithersburg, Inc.	Verfahren zur feststellung von hpv in einer probe
AU2011210734B2 (en)	2010-01-29	2017-02-09	Qiagen Gaithersburg, Inc.	Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
WO2011097407A1 (en)	2010-02-04	2011-08-11	Ico Therapeutics Inc.	Dosing regimens for treating and preventing ocular disorders using c-raf antisense
CN102844435B (zh)	2010-02-22	2017-05-10	库尔纳公司	通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
CA2787657A1 (en)	2010-02-23	2011-09-01	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2011105901A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en)	2010-02-23	2011-09-01	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011112516A1 (en)	2010-03-08	2011-09-15	Ico Therapeutics Inc.	Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
US8906875B2 (en)	2010-03-12	2014-12-09	The Brigham And Women's Hospital, Inc.	Methods of treating vascular inflammatory disorders
US20130281510A1 (en)	2010-03-29	2013-10-24	Kumamoto University	siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
US9102938B2 (en)	2010-04-01	2015-08-11	Alnylam Pharmaceuticals, Inc.	2′ and 5′ modified monomers and oligonucleotides
CA2792561C (en)	2010-04-06	2021-10-26	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of cd274/pd-l1 gene
CN102858979B (zh)	2010-04-09	2018-01-26	库尔纳公司	通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
WO2011133876A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
EP2606057B1 (de)	2010-04-28	2016-06-15	Ionis Pharmaceuticals, Inc.	Modifizierte 5' diphosphat-nukleoside und daraus hergestellte oligomere verbindungen
CN103154014B (zh)	2010-04-28	2015-03-25	Isis制药公司	修饰核苷、其类似物以及由它们制备的寡聚化合物
EP3091027B1 (de)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5'-modifizierte nukleoside und daraus hergestellte oligomere verbindungen
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
CA2994063A1 (en)	2010-04-29	2011-11-10	Ionis Pharmaceuticals, Inc.	Modulation of transthyretin expression
KR101936011B1 (ko)	2010-05-03	2019-01-07	큐알엔에이, 인크.	시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
BR112012028010A2 (pt)	2010-05-03	2017-09-26	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
TWI531370B (zh)	2010-05-14	2016-05-01	可娜公司	藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
AU2011255638B2 (en)	2010-05-19	2016-08-25	Qiagen Gaithersburg, Inc.	Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
CA2799205A1 (en)	2010-05-25	2011-12-01	Qiagen Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
EP3299464B1 (de)	2010-05-26	2019-10-02	CuRNA, Inc.	Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
WO2011153323A2 (en)	2010-06-02	2011-12-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods directed to treating liver fibrosis
WO2011153354A1 (en)	2010-06-03	2011-12-08	Cellay, Inc.	Methods and kits for in situ detection of nucleotide sequences
WO2011156713A1 (en)	2010-06-11	2011-12-15	Vanderbilt University	Multiplexed interferometric detection system and method
WO2011163121A1 (en)	2010-06-21	2011-12-29	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
CA2805318A1 (en)	2010-07-14	2012-01-19	Curna, Inc.	Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
US20130202652A1 (en)	2010-07-30	2013-08-08	Alnylam Pharmaceuticals, Inc.	Methods and compositions for delivery of active agents
US20130323269A1 (en)	2010-07-30	2013-12-05	Muthiah Manoharan	Methods and compositions for delivery of active agents
SG10201508118WA (en)	2010-09-30	2015-11-27	Agency Science Tech & Res	Methods and reagents for detection and treatment of esophageal metaplasia
EP2625197B1 (de)	2010-10-05	2016-06-29	Genentech, Inc.	Smoothened-mutant und verfahren zu seiner anwendung
US8993533B2 (en)	2010-10-06	2015-03-31	Curna, Inc.	Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
US20140031250A1 (en)	2010-10-07	2014-01-30	David Tsai Ting	Biomarkers of Cancer
JP6049623B2 (ja)	2010-10-22	2016-12-21	カッパーアールエヌエー，インコーポレイテッド	α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
US20130210893A1 (en)	2010-10-27	2013-08-15	Curna, Inc.	Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012064824A1 (en)	2010-11-09	2012-05-18	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
EP3260540A1 (de)	2010-11-12	2017-12-27	The General Hospital Corporation	Polycombassoziierte nichtcodierende rnas
JP6071893B2 (ja)	2010-11-23	2017-02-01	カッパーアールエヌエー，インコーポレイテッド	Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
WO2012078967A2 (en)	2010-12-10	2012-06-14	Alnylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (epo) production
EP2648763A4 (de)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
CA2824526C (en)	2011-01-11	2020-07-07	Alnylam Pharmaceuticals, Inc.	Pegylated lipids and their use for drug delivery
US9045749B2 (en)	2011-01-14	2015-06-02	The General Hospital Corporation	Methods targeting miR-128 for regulating cholesterol/lipid metabolism
PT2670411T (pt)	2011-02-02	2019-06-18	Excaliard Pharmaceuticals Inc	Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
WO2012113775A1 (en)	2011-02-21	2012-08-30	University Of Zurich	Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
US9562853B2 (en)	2011-02-22	2017-02-07	Vanderbilt University	Nonaqueous backscattering interferometric methods
AU2012220575B2 (en)	2011-02-24	2017-01-12	Qiagen Gaithersburg, Inc.	Materials and methods for detection of HPV nucleic acid
US9175290B2 (en)	2011-03-29	2015-11-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of TMPRSS6 gene
US9593330B2 (en)	2011-06-09	2017-03-14	Curna, Inc.	Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
CN103890000B (zh)	2011-06-21	2017-09-01	阿尔尼拉姆医药品有限公司	血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
US9068184B2 (en)	2011-06-21	2015-06-30	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibition of expression of protein C (PROC) genes
KR102369777B1 (ko)	2011-06-21	2022-03-03	알닐람 파마슈티칼스 인코포레이티드	아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP4134433A1 (de)	2011-06-23	2023-02-15	Alnylam Pharmaceuticals, Inc.	Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
WO2013040499A1 (en)	2011-09-14	2013-03-21	Northwestern University	Nanoconjugates able to cross the blood-brain barrier
DK2756080T3 (da)	2011-09-14	2019-05-20	Translate Bio Ma Inc	Multimeriske oligonukleotidforbindelser
US9701623B2 (en)	2011-09-27	2017-07-11	Alnylam Pharmaceuticals, Inc.	Di-aliphatic substituted pegylated lipids
AU2012322788B2 (en)	2011-10-11	2018-01-04	The Brigham And Women's Hospital, Inc.	Micrornas in neurodegenerative disorders
CN104080958A (zh)	2011-10-19	2014-10-01	纽亘技术公司	用于定向核酸扩增和测序的组合物和方法
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
JP2015505241A (ja)	2011-12-12	2015-02-19	セレー，インコーポレイテッド	生物学的試料中の標的核酸の室温インサイチュ検出のための方法およびキット
SG10201604896TA (en)	2011-12-16	2016-08-30	Moderna Therapeutics Inc	Modified nucleoside, nucleotide, and nucleic acid compositions
GB2513793B (en)	2012-01-26	2016-11-02	Nugen Tech Inc	Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
KR20140136488A (ko)	2012-03-15	2014-11-28	큐알엔에이, 인크.	뇌 유래 신경영양 인자（ｂｄｎｆ）에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자（ｂｄｎｆ）관련 질환의 치료
JP2015513913A (ja)	2012-04-02	2015-05-18	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ポリヌクレオチド
WO2013151666A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013159091A2 (en)	2012-04-20	2013-10-24	Aptamir Therapeutics, Inc.	Mirna modulators of thermogenesis
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
EP3597741A1 (de)	2012-04-27	2020-01-22	Duke University	Genetische korrektur mutierter gene
US9273949B2 (en)	2012-05-11	2016-03-01	Vanderbilt University	Backscattering interferometric methods
AU2013262663A1 (en)	2012-05-16	2015-01-22	The General Hospital Corporation D/B/A Massachusetts General Hospital	Compositions and methods for modulating gene expression
EP2850186B1 (de)	2012-05-16	2018-12-19	Translate Bio MA, Inc.	Zusammensetzungen und verfahren zur modulation der expression der smn-genfamilie
JP6181751B2 (ja)	2012-06-18	2017-08-16	ニューゲンテクノロジーズ，インコーポレイテッド	望まれない核酸配列のネガティブ選択のための組成物および方法
US20150011396A1 (en)	2012-07-09	2015-01-08	Benjamin G. Schroeder	Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
EP2880161A1 (de)	2012-08-03	2015-06-10	Aptamir Therapeutics, Inc.	Abgabe von zellspezifischen mirna-modulatoren zur behandlung von adipositas und verwandten erkrankungen
WO2014070460A1 (en)	2012-10-31	2014-05-08	Cellay, Inc.	Methods and kits for performing in situ hybridization
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
JP2016504050A (ja)	2013-01-17	2016-02-12	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
WO2014159813A1 (en)	2013-03-13	2014-10-02	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US10258698B2 (en)	2013-03-14	2019-04-16	Modernatx, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
SI2970974T1 (sl)	2013-03-14	2017-12-29	Alnylam Pharmaceuticals, Inc.	Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
US20140274738A1 (en)	2013-03-15	2014-09-18	Nugen Technologies, Inc.	Sequential sequencing
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2978446B1 (de)	2013-03-27	2020-03-04	The General Hospital Corporation	Anti-cd33 antikörper zur behandlung von morbus alzheimer
US10590412B2 (en)	2013-04-19	2020-03-17	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation nucleic acids through nonsense mediated decay
LT2999785T (lt)	2013-05-22	2018-07-25	Alnylam Pharmaceuticals, Inc.	Serpina1 irna kompozicijos ir jų panaudojimo būdai
ES2862125T3 (es)	2013-06-13	2021-10-07	Antisense Therapeutics Ltd	Terapia combinada para acromegalia
EP3019619B1 (de)	2013-07-11	2021-08-25	ModernaTX, Inc.	Zusammensetzungen mit synthetischen polynukleotiden zur codierung von crispr-verwandten proteinen und synthetischen sgrnas und verfahren zur verwendung
DK3041854T3 (da)	2013-08-08	2020-03-02	Scripps Research Inst	En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
EP3041934A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimäre polynukleotide
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
EP3052626A1 (de)	2013-10-02	2016-08-10	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
SG11201602631XA (en)	2013-10-04	2016-05-30	Alnylam Pharmaceuticals Inc	Compositions and methods for inhibiting expression of the alas1 gene
WO2015069920A1 (en)	2013-11-07	2015-05-14	Cellay, Inc.	Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers
JP6525473B2 (ja)	2013-11-13	2019-06-05	ニューゲンテクノロジーズ，インコーポレイテッド	複製物配列決定リードを同定するための組成物および方法
WO2015075557A2 (en)	2013-11-22	2015-05-28	Mina Alpha Limited	C/ebp alpha compositions and methods of use
CA2844640A1 (en)	2013-12-06	2015-06-06	The University Of British Columbia	Method for treatment of castration-resistant prostate cancer
SG11201604692UA (en)	2013-12-12	2016-07-28	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
US20170044232A1 (en)	2014-02-04	2017-02-16	Genentech, Inc.	Mutant smoothened and methods of using the same
JP6594902B2 (ja)	2014-02-11	2019-10-23	アルナイラムファーマシューティカルズ，インコーポレイテッド	ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物及びその使用方法
WO2015131107A1 (en)	2014-02-28	2015-09-03	Nugen Technologies, Inc.	Reduced representation bisulfite sequencing with diversity adaptors
EP3943607A1 (de)	2014-04-09	2022-01-26	The Scripps Research Institute	Import von unnatürlichen oder modifizierten nukleosid-triphosphaten in zellen mittels nukleinsäure-triphosphattransportern
WO2015161170A2 (en)	2014-04-17	2015-10-22	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of smn2 splicing in a subject
WO2015171918A2 (en)	2014-05-07	2015-11-12	Louisiana State University And Agricultural And Mechanical College	Compositions and uses for treatment thereof
WO2015175510A1 (en)	2014-05-12	2015-11-19	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating a serpinc1-associated disorder
EA201692370A1 (ru)	2014-05-22	2017-03-31	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
CA2950878C (en)	2014-06-10	2024-01-23	Erasmus University Medical Center Rotterdam	Antisense oligonucleotides useful in treatment of pompe disease
US10301624B2 (en)	2014-06-25	2019-05-28	The General Hospital Corporation	Targeting human satellite II (HSATII)
EP4159741A1 (de)	2014-07-16	2023-04-05	ModernaTX, Inc.	Verfahren zur herstellung eines chimären polynukleotids zur kodierung eines polypeptids mit einer triazolhaltigen internukleotid-bindung
EP3171895A1 (de)	2014-07-23	2017-05-31	Modernatx, Inc.	Modifizierte polynukleotide zur herstellung von intrabodys
IL250302B (en)	2014-07-31	2022-07-01	Uab Research Foundation	Apoe mimetic peptides with high potency to clear plasma cholesterol
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10385343B2 (en)	2014-08-29	2019-08-20	Children's Medical Center Corporation	Methods and compositions for the treatment of cancer
EP3191591A1 (de)	2014-09-12	2017-07-19	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
US10556020B2 (en)	2014-09-26	2020-02-11	University Of Massachusetts	RNA-modulating agents
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (de)	2014-10-30	2021-04-07	Genzyme Corporation	Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CN107250362B (zh)	2014-11-17	2021-10-22	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
WO2016081060A2 (en)	2014-11-18	2016-05-26	Agiltron, Inc.	Systems for detecting target biological molecules
CN107106493A (zh)	2014-11-21	2017-08-29	西北大学	球形核酸纳米颗粒缀合物的序列特异性细胞摄取
WO2016094342A1 (en)	2014-12-08	2016-06-16	The Board Of Regents Of The University Of Texas System	Lipocationic polymers and uses thereof
AU2015364508A1 (en)	2014-12-18	2017-07-06	Alnylam Pharmaceuticals, Inc.	ReversirTM compounds
EP3247988A4 (de)	2015-01-23	2018-12-19	Vanderbilt University	Robustes interferometer und verfahren zur verwendung davon
JP6929791B2 (ja)	2015-02-09	2021-09-01	デュークユニバーシティ	エピゲノム編集のための組成物および方法
WO2016130806A2 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016135559A2 (en)	2015-02-23	2016-09-01	Crispr Therapeutics Ag	Materials and methods for treatment of human genetic diseases including hemoglobinopathies
US9708647B2 (en)	2015-03-23	2017-07-18	Insilixa, Inc.	Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays
EP3283502A4 (de)	2015-04-07	2019-04-03	The General Hospital Corporation	Verfahren zur reaktivierung von genen auf dem inaktiven x-chromosom
WO2016164746A1 (en)	2015-04-08	2016-10-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP3307316A1 (de)	2015-06-12	2018-04-18	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CN108139375A (zh)	2015-06-26	2018-06-08	贝斯以色列女执事医疗中心股份有限公司	靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
AU2016287499B2 (en)	2015-06-29	2022-08-04	Caris Science, Inc.	Therapeutic oligonucleotides
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CA2989970A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
US10941176B2 (en)	2015-07-28	2021-03-09	Caris Science, Inc.	Therapeutic oligonucleotides
EP3344769B1 (de)	2015-09-02	2024-04-17	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (pd-l1) irna-kompositionen und methoden zu deren verwendung
US9499861B1 (en)	2015-09-10	2016-11-22	Insilixa, Inc.	Methods and systems for multiplex quantitative nucleic acid amplification
KR20240027890A (ko)	2015-09-14	2024-03-04	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	지질양이온성 덴드리머 및 이의 용도
EP3353297A1 (de)	2015-09-24	2018-08-01	Crispr Therapeutics AG	Neuartige familie von rna-programmierbaren endonukleasen und deren verwendung in der genomeditierung und anderen anwendungen
WO2017066497A2 (en)	2015-10-13	2017-04-20	Duke University	Genome engineering with type i crispr systems in eukaryotic cells
EP4279084A1 (de)	2015-10-28	2023-11-22	Vertex Pharmaceuticals Inc.	Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
EP3370734B1 (de)	2015-11-05	2023-01-04	Children's Hospital Los Angeles	Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
CN109328231A (zh)	2015-11-06	2019-02-12	克里斯普治疗股份公司	用于治疗1a型糖原贮积病的材料和方法
CA3005878A1 (en)	2015-11-19	2017-05-26	The Brigham And Women's Hospital, Inc.	Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
AU2016364667A1 (en)	2015-12-01	2018-06-21	Crispr Therapeutics Ag	Materials and methods for treatment of Alpha-1 antitrypsin deficiency
EP3387127A1 (de)	2015-12-07	2018-10-17	Erasmus University Medical Center Rotterdam	Enzymatische ersatztherapie und antisense-therapie für pompe-krankheit
WO2017106767A1 (en)	2015-12-18	2017-06-22	The Scripps Research Institute	Production of unnatural nucleotides using a crispr/cas9 system
CA3009308A1 (en)	2015-12-23	2017-06-29	Chad Albert COWAN	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
EP3408649B1 (de)	2016-01-29	2023-06-14	Vanderbilt University	Interferometrie mit antwortfunktion in freier lösung
WO2017134529A1 (en)	2016-02-02	2017-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
WO2017141109A1 (en)	2016-02-18	2017-08-24	Crispr Therapeutics Ag	Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
CA3054284A1 (en)	2016-02-25	2017-08-31	The Brigham And Women's Hospital, Inc.	Treatment methods for fibrosis targeting smoc2
WO2017155858A1 (en)	2016-03-07	2017-09-14	Insilixa, Inc.	Nucleic acid sequence identification using solid-phase cyclic single base extension
US11083799B2 (en)	2016-03-16	2021-08-10	Crispr Therapeutics Ag	Materials and methods for treatment of hereditary haemochromatosis
KR20190008843A (ko)	2016-03-18	2019-01-25	카리스 싸이언스, 인코포레이티드	올리고뉴클레오티드 프로브 및 이의 용도
KR102351329B1 (ko)	2016-04-18	2022-01-18	크리스퍼 테라퓨틱스 아게	혈색소병증의 치료를 위한 물질 및 방법
WO2017191503A1 (en)	2016-05-05	2017-11-09	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
CN114656378A (zh)	2016-05-16	2022-06-24	得克萨斯州大学***董事会	阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
IL306052A (en)	2016-05-25	2023-11-01	Caris Science Inc	Oligonucleotide probes and their uses
US20190256845A1 (en)	2016-06-10	2019-08-22	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
DK3475295T3 (da)	2016-06-24	2022-10-24	Scripps Research Inst	Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
US11427838B2 (en)	2016-06-29	2022-08-30	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
EP3478313B1 (de)	2016-06-29	2022-05-04	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung von amyotropher lateralsklerose (als) und anderen verwandten erkrankungen
EP3478828A1 (de)	2016-06-29	2019-05-08	Crispr Therapeutics AG	Materialien und verfahren zur behandlung von friedreich-ataxie und anderen verwandten erkrankungen
AU2017292173B2 (en)	2016-07-06	2022-01-13	Vertex Pharmaceuticals Incorporated	Materials and methods for treatment of pain related disorders
JP7305534B2 (ja)	2016-07-06	2023-07-10	バーテックスファーマシューティカルズインコーポレイテッド	疼痛関連障害を処置するための物質及び方法
WO2018007871A1 (en)	2016-07-08	2018-01-11	Crispr Therapeutics Ag	Materials and methods for treatment of transthyretin amyloidosis
EP3481430A4 (de)	2016-07-11	2020-04-01	Translate Bio Ma, Inc.	Nukleinsäurekonjugate und verwendungen davon
WO2018020323A2 (en)	2016-07-25	2018-02-01	Crispr Therapeutics Ag	Materials and methods for treatment of fatty acid disorders
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Antisense oligomeric compound for Pompe disease
WO2018081817A2 (en)	2016-10-31	2018-05-03	University Of Massachusetts	Targeting microrna-101-3p in cancer therapy
TW202313978A (zh)	2016-11-23	2023-04-01	美商阿尼拉製藥公司	絲胺酸蛋白酶抑制因子Ａ１ｉＲＮＡ組成物及其使用方法
AU2017378153B2 (en)	2016-12-13	2024-03-28	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
WO2018112320A1 (en)	2016-12-16	2018-06-21	Alnylam Pharmaceuticals, Inc.	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
WO2018136758A1 (en)	2017-01-23	2018-07-26	Regeneron Pharmaceuticals, Inc.	Hsd17b13 variants and uses thereof
JP2020508056A (ja)	2017-02-22	2020-03-19	クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲＴｈｅｒａｐｅｕｔｉｃｓＡＧ	遺伝子編集のための組成物および方法
US20200040061A1 (en)	2017-02-22	2020-02-06	Crispr Therapeutics Ag	Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
US20200216857A1 (en)	2017-02-22	2020-07-09	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US11407997B2 (en)	2017-02-22	2022-08-09	Crispr Therapeutics Ag	Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
WO2018154439A1 (en)	2017-02-22	2018-08-30	Crispr Therapeutics Ag	Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
KR20200015895A (ko)	2017-04-18	2020-02-13	알닐람 파마슈티칼스 인코포레이티드	B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
US11622977B2 (en)	2017-05-12	2023-04-11	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
CA3069321A1 (en)	2017-07-11	2019-01-17	Synthorx, Inc.	Incorporation of unnatural nucleotides and methods thereof
AU2018301477A1 (en)	2017-07-13	2020-02-27	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
MX2020001332A (es)	2017-08-03	2020-09-09	Synthorx Inc	Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
US11447773B2 (en)	2017-09-08	2022-09-20	Mina Therapeutics Limited	Stabilized HNF4A saRNA compositions and methods of use
EP4219715A3 (de)	2017-09-08	2023-09-06	MiNA Therapeutics Limited	Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
US11999953B2 (en)	2017-09-13	2024-06-04	The Children's Medical Center Corporation	Compositions and methods for treating transposon associated diseases
WO2019079527A1 (en)	2017-10-17	2019-04-25	Casebia Therapeutics Limited Liability Partnership	COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
US11099202B2 (en)	2017-10-20	2021-08-24	Tecan Genomics, Inc.	Reagent delivery system
MA50849A (fr)	2017-10-26	2020-09-02	Vertex Pharma	Substances et procédés pour le traitement d'hémoglobinopathies
EP3704252A1 (de)	2017-11-01	2020-09-09	Alnylam Pharmaceuticals, Inc.	Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
EP3707155A2 (de)	2017-11-09	2020-09-16	Vertex Pharmaceuticals Incorporated	Crispr/cas-systeme für die behandlung von dmd
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
JP7522656B2 (ja)	2017-11-21	2024-07-25	クリスパーセラピューティクスアーゲー	常染色体優性網膜色素変性の処置のための材料および方法
AU2018378479A1 (en)	2017-12-05	2020-06-18	Vertex Pharmaceuticals Incorporated	CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
EP3724332A1 (de)	2017-12-14	2020-10-21	CRISPR Therapeutics AG	Neuartige rna-programmierbare endonukleasesysteme und deren verwendung in der genombearbeitung und anderen anwendungen
KR20200110655A (ko)	2017-12-18	2020-09-24	알닐람 파마슈티칼스 인코포레이티드	고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법
EP3728595A1 (de)	2017-12-21	2020-10-28	CRISPR Therapeutics AG	Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp)
WO2019123429A1 (en)	2017-12-21	2019-06-27	Casebia Therapeutics Llp	Materials and methods for treatment of usher syndrome type 2a
MA51637A (fr)	2018-01-12	2020-11-18	Bayer Healthcare Llc	Compositions et méthodes pour l'édition génique par ciblage de la transferrine
WO2019147743A1 (en)	2018-01-26	2019-08-01	Massachusetts Institute Of Technology	Structure-guided chemical modification of guide rna and its applications
WO2019150196A1 (en)	2018-02-05	2019-08-08	Crispr Therapeutics Ag	Materials and methods for treatment of hemoglobinopathies
EP3749768A1 (de)	2018-02-05	2020-12-16	Vertex Pharmaceuticals Incorporated	Materialien und verfahren zur behandlung von hämoglobinopathien
MA51869A (fr)	2018-02-16	2020-12-23	Bayer Healthcare Llc	Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
MX2020008772A (es)	2018-02-26	2020-10-01	Synthorx Inc	Conjugados de il-15, y sus usos.
CN112424348A (zh)	2018-03-19	2021-02-26	克里斯珀医疗股份公司	新颖的rna-可编程的内切核酸酶***及其用途
US12049631B2 (en)	2018-03-30	2024-07-30	Rheinische Friedrich-Wilhelms-Universitat Bonn	Aptamers for targeted activation of T cell-mediated immunity
EP3772928A4 (de)	2018-04-06	2021-12-29	Children's Medical Center Corporation	Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
EP4242307A3 (de)	2018-04-12	2023-12-27	MiNA Therapeutics Limited	Sirt1-sarna kompositionen und methoden zu deren verwendung
WO2019204668A1 (en)	2018-04-18	2019-10-24	Casebia Therapeutics Limited Liability Partnership	Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
JP7480062B2 (ja)	2018-04-27	2024-05-14	シアトルチルドレンズホスピタル（ディービーエイシアトルチルドレンズリサーチインスティテュート）	ラパマイシン耐性細胞
CA3098623A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
ES2967713T3 (es)	2018-05-14	2024-05-03	Alnylam Pharmaceuticals Inc	Composiciones de ARNi de angiotensinógeno (AGT) y métodos de uso de las mismas
EA202190528A1 (ru)	2018-08-13	2021-04-23	Элнилэм Фармасьютикалз, Инк.	КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2020037125A1 (en)	2018-08-16	2020-02-20	Alnylam Pharmaceuticals Inc.	Compositions and methods for inhibiting expression of the lect2 gene
WO2020047229A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
CA3105385A1 (en)	2018-09-18	2020-03-26	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
TW202028465A (zh)	2018-09-28	2020-08-01	美商阿尼拉製藥公司	甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關眼部疾病之使用方法
EP3867377A1 (de)	2018-10-17	2021-08-25	CRISPR Therapeutics AG	Zusammensetzungen und verfahren zur abgabe von transgenen
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
EA202191736A1 (ru)	2018-12-20	2021-10-01	Вир Байотекнолоджи, Инк.	Комбинированная терапия hbv
CN113631709A (zh)	2018-12-20	2021-11-09	普拉克西斯精密药物股份有限公司	用于治疗kcnt1相关病症的组合物和方法
EP3911335A1 (de)	2019-01-16	2021-11-24	Genzyme Corporation	Serpinc1-irna-zusammensetzungen und verfahren zur verwendung davon
BR112021014415A2 (pt)	2019-02-06	2021-09-21	Synthorx, Inc.	Conjugados de il-2 e métodos de uso dos mesmos
MA54951A (fr)	2019-02-15	2021-12-22	Bayer Healthcare Llc	Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
WO2020171889A1 (en)	2019-02-19	2020-08-27	University Of Rochester	Blocking lipid accumulation or inflammation in thyroid eye disease
EP3937963A2 (de)	2019-03-12	2022-01-19	CRISPR Therapeutics AG	Neuartige rna-programmierbare high-fidelity-endonukleasesysteme und verwendungen davon
EP3937780A4 (de)	2019-03-14	2022-12-07	InSilixa, Inc.	Verfahren und systeme zur zeitgesteuerten fluoreszenzbasierten detektion
WO2020208361A1 (en)	2019-04-12	2020-10-15	Mina Therapeutics Limited	Sirt1-sarna compositions and methods of use
BR112021022806A2 (pt)	2019-05-13	2022-01-25	Vir Biotechnology Inc	Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit
AU2020279101A1 (en)	2019-05-17	2021-11-18	Alnylam Pharmaceuticals, Inc.	Oral delivery of oligonucleotides
US11879145B2 (en)	2019-06-14	2024-01-23	The Scripps Research Institute	Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202120128A (zh)	2019-08-15	2021-06-01	美商欣爍克斯公司	使用ｉｌ－２接合物之免疫腫瘤學組合療法
JP2022545101A (ja)	2019-08-19	2022-10-25	ミナセラピューティクスリミテッド	オリゴヌクレオチドコンジュゲート組成物および使用方法
KR20220051355A (ko)	2019-08-23	2022-04-26	신톡스, 인크.	Il-15 콘쥬게이트 및 이의 용도
EP4025694A1 (de)	2019-09-03	2022-07-13	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum hemmen der lect2-genexpression
JP2022547078A (ja)	2019-09-10	2022-11-10	シンソークス，インコーポレイテッド	Ｉｌ－２コンジュゲートおよび自己免疫疾患を治療するための使用方法
WO2021067747A1 (en)	2019-10-04	2021-04-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing ugt1a1 gene expression
US20240141358A1 (en)	2019-10-18	2024-05-02	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
JP2022553348A (ja)	2019-10-22	2022-12-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分Ｃ３ｉＲＮＡ組成物およびその使用方法
JP2023500661A (ja)	2019-11-01	2023-01-10	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
EP4051796A1 (de)	2019-11-01	2022-09-07	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
IL291786A (en)	2019-11-04	2022-06-01	Synthorx Inc	Interleukin 10 conjugates and their use
AU2020378414A1 (en)	2019-11-06	2022-05-26	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
WO2021092145A1 (en)	2019-11-06	2021-05-14	Alnylam Pharmaceuticals, Inc.	Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021096763A1 (en)	2019-11-13	2021-05-20	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
EP4061945A1 (de)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
CA3164599A1 (en)	2019-12-13	2021-06-17	Alnylam Pharmaceuticals, Inc.	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (zh)	2019-12-16	2021-10-16	美商阿尼拉製藥公司	含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
WO2021122944A1 (en)	2019-12-18	2021-06-24	Alia Therapeutics Srl	Compositions and methods for treating retinitis pigmentosa
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CN113275053A (zh)	2020-02-03	2021-08-20	帝肯基因组学公司	试剂存储***
TW202140786A (zh)	2020-02-10	2021-11-01	美商艾爾妮蘭製藥公司	用於靜默ｖｅｇｆ－ａ表現之組合物及方法
CA3171654A1 (en)	2020-02-18	2021-08-26	Alnylam Pharmaceuticals, Inc.	Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
EP4114947A1 (de)	2020-03-05	2023-01-11	Alnylam Pharmaceuticals, Inc.	Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
WO2021178778A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of transthyretin (ttr)
AU2021232014A1 (en)	2020-03-06	2022-10-06	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (KHK) IRNA compositions and methods of use thereof
EP4121534A1 (de)	2020-03-18	2023-01-25	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
EP4127171A2 (de)	2020-03-30	2023-02-08	Alnylam Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
MX2022012493A (es)	2020-04-06	2022-10-27	Alnylam Pharmaceuticals Inc	Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
US20230159933A1 (en)	2020-04-07	2023-05-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
WO2021222065A1 (en)	2020-04-27	2021-11-04	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
JP2023523790A (ja)	2020-04-30	2023-06-07	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231691A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
EP4150086A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
WO2021231680A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
EP4150088A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von argininosuccinat-synthetase (ass1)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150090A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von otoflin (otof)
EP4150087A1 (de)	2020-05-15	2023-03-22	Korro Bio, Inc.	Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung des gap-junction-proteins beta 2 (gjb2)
US20230183707A1 (en)	2020-05-21	2023-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
KR20230016201A (ko)	2020-05-22	2023-02-01	웨이브 라이프 사이언시스 리미티드	이중 가닥 올리고뉴클레오티드 조성물 및 이와 관련된 방법
US11408000B2 (en)	2020-06-03	2022-08-09	Triplet Therapeutics, Inc.	Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
IL299063A (en)	2020-06-18	2023-02-01	Alnylam Pharmaceuticals Inc	Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
EP4171747A1 (de)	2020-06-24	2023-05-03	VIR Biotechnology, Inc.	Manipulierte hepatitis-b-virus-neutralisierende antikörper und verwendungen davon
WO2021263026A1 (en)	2020-06-25	2021-12-30	Synthorx, Inc.	Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
BR112023000428A2 (pt)	2020-07-10	2023-03-14	Inst Nat Sante Rech Med	Métodos e composições para tratar epilepsia
US20230257745A1 (en)	2020-07-10	2023-08-17	Alnylam Pharmaceuticals, Inc.	Circular siRNAs
EP4217489A1 (de)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
US20230392134A1 (en)	2020-09-30	2023-12-07	Crispr Therapeutics Ag	Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076291A1 (en)	2020-10-05	2022-04-14	Alnylam Pharmaceuticals, Inc.	G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
AU2021356610A1 (en)	2020-10-09	2023-06-15	Synthorx, Inc.	Immuno oncology therapies with il-2 conjugates
EP4225376A1 (de)	2020-10-09	2023-08-16	Synthorx, Inc.	Immunonkologische kombinationstherapie mit il-2-konjugaten und pembrolizumab
EP4232582A1 (de)	2020-10-23	2023-08-30	Alnylam Pharmaceuticals, Inc.	Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
MX2023005490A (es)	2020-11-13	2023-05-23	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso.
WO2022125490A1 (en)	2020-12-08	2022-06-16	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
EP4271695A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Auf 2'-modifiziertem nukleosid basierende oligonukleotid-prodrugs
EP4271696A2 (de)	2020-12-31	2023-11-08	Alnylam Pharmaceuticals, Inc.	Oligonukleotid-prodrugs auf basis von mit cyclischem disulfid modifiziertem phosphat
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508714A (ja)	2021-02-12	2024-02-28	アルナイラムファーマシューティカルズ，インコーポレイテッド	スーパーオキシドジスムターゼ１－（ＳＯＤ１－）関連神経変性疾患を治療または予防するためのスーパーオキシドジスムターゼ１（ＳＯＤ１）ｉＲＮＡ組成物およびその使用方法
TW202245843A (zh)	2021-02-12	2022-12-01	美商欣爍克斯公司	Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
TW202302148A (zh)	2021-02-12	2023-01-16	美商欣爍克斯公司	使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
CN117222739A (zh)	2021-02-25	2023-12-12	阿尔尼拉姆医药品有限公司	朊病毒蛋白(prnp)irna组合物和其使用方法
CA3211059A1 (en)	2021-02-26	2022-09-01	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
BR112023017737A2 (pt)	2021-03-04	2023-10-03	Alnylam Pharmaceuticals Inc	Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
EP4305169A1 (de)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
KR20230160872A (ko)	2021-03-26	2023-11-24	미나 테라퓨틱스 리미티드	Tmem173 sarna 조성물 및 사용 방법
AU2022246786A1 (en)	2021-03-29	2023-10-05	Alnylam Pharmaceuticals, Inc.	Huntingtin (htt) irna agent compositions and methods of use thereof
WO2022212153A1 (en)	2021-04-01	2022-10-06	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022226291A1 (en)	2021-04-22	2022-10-27	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating cancer
WO2022231999A1 (en)	2021-04-26	2022-11-03	Alnylam Pharmaceuticals, Inc.	Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (de)	2021-04-29	2024-03-06	Alnylam Pharmaceuticals, Inc.	Signalwandler und aktivator von transkriptionsfaktor 6 (stat6)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4341401A1 (de)	2021-05-18	2024-03-27	Alnylam Pharmaceuticals, Inc.	Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
WO2022256395A1 (en)	2021-06-02	2022-12-08	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4346904A1 (de)	2021-06-03	2024-04-10	Synthorx, Inc.	Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und cetuximab
BR112023025224A2 (pt)	2021-06-04	2024-02-27	Alnylam Pharmaceuticals Inc	Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
JP2024523000A (ja)	2021-06-08	2024-06-25	アルナイラムファーマシューティカルズ，インコーポレイテッド	シュタルガルト病及び／又は網膜結合タンパク質４（ｒｂｐ４）関連障害を治療又は予防するための組成物及び方法
EP4101928A1 (de)	2021-06-11	2022-12-14	Bayer AG	Programmierbare typ-v-rna-endonukleasesysteme
IL308896A (en)	2021-06-11	2024-01-01	Bayer Ag	Programmable type V RNA endoclase systems
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
EP4363574A1 (de)	2021-06-29	2024-05-08	Korro Bio, Inc.	Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
EP4363580A1 (de)	2021-06-30	2024-05-08	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur behandlung einer angiotensinogen- (gt-) assoziierten erkrankung
EP4367237A2 (de)	2021-07-09	2024-05-15	Alnylam Pharmaceuticals, Inc.	Bis-rnai-verbindungen zur zns-verabreichung
WO2023285431A1 (en)	2021-07-12	2023-01-19	Alia Therapeutics Srl	Compositions and methods for allele specific treatment of retinitis pigmentosa
EP4373934A1 (de)	2021-07-19	2024-05-29	Alnylam Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur behandlung von patienten mit oder mit einem risiko zur entwicklung einer nichtprimären hyperoxalurieerkrankung oder -störung
AU2022314619A1 (en)	2021-07-21	2024-01-04	Alnylam Pharmaceuticals, Inc.	Metabolic disorder-associated target gene irna compositions and methods of use thereof
JP2024528701A (ja)	2021-07-23	2024-07-30	アルナイラムファーマシューティカルズ，インコーポレイテッド	ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法
EP4377458A1 (de)	2021-07-29	2024-06-05	Alnylam Pharmaceuticals, Inc.	3-hydroxy-3-methylglutaryl-coa-reduktase (hmgcr)-irna-zusammensetzungen und verfahren zur verwendung davon
TW202328445A (zh)	2021-08-03	2023-07-16	美商艾拉倫製藥股份有限公司	甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法
WO2023014765A1 (en)	2021-08-04	2023-02-09	Alnylam Pharmaceuticals, Inc.	iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
WO2023019246A1 (en)	2021-08-13	2023-02-16	Alnylam Pharmaceuticals, Inc.	Factor xii (f12) irna compositions and methods of use thereof
EP4144841A1 (de)	2021-09-07	2023-03-08	Bayer AG	Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
EP4401742A2 (de)	2021-09-17	2024-07-24	Alnylam Pharmaceuticals, Inc.	Irna-zusammensetzungen und verfahren zur dämpfung der komplementkomponente 3 (c3)
IL311454A (en)	2021-09-20	2024-05-01	Alnylam Pharmaceuticals Inc	Inhibin subunit E (INHBE) modulator compositions and methods of using them
KR20240101590A (ko)	2021-10-15	2024-07-02	알닐람 파마슈티칼스 인코포레이티드	간외 전달 irna 조성물 및 이를 이용하는 방법
CA3234835A1 (en)	2021-10-22	2023-04-27	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
AR127477A1 (es)	2021-10-29	2024-01-31	Alnylam Pharmaceuticals Inc	COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS
TW202334418A (zh)	2021-10-29	2023-09-01	美商艾拉倫製藥股份有限公司	杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2023099884A1 (en)	2021-12-01	2023-06-08	Mina Therapeutics Limited	Pax6 sarna compositions and methods of use
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118349A1 (en)	2021-12-21	2023-06-29	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2023118068A1 (en)	2021-12-23	2023-06-29	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2023122750A1 (en)	2021-12-23	2023-06-29	Synthorx, Inc.	Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en)	2022-01-24	2023-07-27	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023166425A1 (en)	2022-03-01	2023-09-07	Crispr Therapeutics Ag	Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023170435A1 (en)	2022-03-07	2023-09-14	Mina Therapeutics Limited	Il10 sarna compositions and methods of use
WO2023194359A1 (en)	2022-04-04	2023-10-12	Alia Therapeutics Srl	Compositions and methods for treatment of usher syndrome type 2a
WO2023220744A2 (en)	2022-05-13	2023-11-16	Alnylam Pharmaceuticals, Inc.	Single-stranded loop oligonucleotides
WO2023237587A1 (en)	2022-06-10	2023-12-14	Bayer Aktiengesellschaft	Novel small type v rna programmable endonuclease systems
WO2024006999A2 (en)	2022-06-30	2024-01-04	Alnylam Pharmaceuticals, Inc.	Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en)	2022-08-18	2024-02-22	Alnylam Pharmaceuticals, Inc.	Universal non-targeting sirna compositions and methods of use thereof
WO2024059165A1 (en)	2022-09-15	2024-03-21	Alnylam Pharmaceuticals, Inc.	17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en)	2022-09-16	2024-03-21	Alia Therapeutics Srl	Enqp type ii cas proteins and applications thereof
WO2024073732A1 (en)	2022-09-30	2024-04-04	Alnylam Pharmaceuticals, Inc.	Modified double-stranded rna agents
WO2024105162A1 (en)	2022-11-16	2024-05-23	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2024129743A2 (en)	2022-12-13	2024-06-20	Bluerock Therapeutics Lp	Engineered type v rna programmable endonucleases and their uses
WO2024136899A1 (en)	2022-12-21	2024-06-27	Synthorx, Inc.	Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024134199A1 (en)	2022-12-22	2024-06-27	Mina Therapeutics Limited	Chemically modified sarna compositions and methods of use
WO2024149810A2 (en)	2023-01-11	2024-07-18	Alia Therapeutics Srl	Type ii cas proteins and applications thereof
WO2024168010A2 (en)	2023-02-09	2024-08-15	Alnylam Pharmaceuticals, Inc.	Reversir molecules and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1254525A (en) *	1983-04-13	1989-05-23	Christine L. Brakel	Kit for terminally chemically labeling dna
JPS60256059A (ja) *	1984-06-01	1985-12-17	Fujirebio Inc	ポリヌクレオチドの測定法
US4760017A (en) *	1985-12-23	1988-07-26	E. I. Du Pont De Nemours And Company	Arabinonucleic acid probes for DNA/RNA assays
JPS638396A (ja) *	1986-06-30	1988-01-14	Wakunaga Pharmaceut Co Ltd	ポリ標識化オリゴヌクレオチド誘導体

1988
- 1988-02-26 US US07/160,607 patent/US5082830A/en not_active Expired - Lifetime
1989
- 1989-02-24 DE DE68928405T patent/DE68928405T2/de not_active Expired - Lifetime
- 1989-02-24 EP EP89103252A patent/EP0330221B1/de not_active Revoked
- 1989-02-24 EP EP97105383A patent/EP0783000A3/de not_active Withdrawn
- 1989-02-24 CA CA000592103A patent/CA1335961C/en not_active Expired - Lifetime
- 1989-02-25 JP JP01044981A patent/JP3083297B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE68928405T2 (de)	1998-06-18
EP0783000A2 (de)	1997-07-09
US5082830A (en)	1992-01-21
JP3083297B2 (ja)	2000-09-04
JPH025900A (ja)	1990-01-10
EP0330221B1 (de)	1997-10-29
CA1335961C (en)	1995-06-20
EP0783000A3 (de)	1997-11-12
EP0330221A2 (de)	1989-08-30
EP0330221A3 (de)	1991-04-17

Legal Events

Date	Code	Title	Description
1998-10-29	8363	Opposition against the patent

Publication	Publication Date	Title
DE68928405D1 (de)	1997-12-04	Endmarkierte Nukleotid-Sonde
DK103389A (da)	1989-09-05	Forbedret braender
DK594089A (da)	1990-05-26	Udvidet nukleotidsekvens
ES2023618A4 (es)	1992-02-01	Secuenciacion de oligosacarido
TR23266A (tr)	1989-08-04	Gizli
DK23489D0 (da)	1989-01-19	Nucleosidderivater
DK564088A (da)	1989-04-10	Nukleosidderivater
DK0409039T3 (da)	1995-04-24	Bioreaktor
DK668088A (da)	1989-05-31	Hysterografisk instrument
DK4689D0 (da)	1989-01-06	Biosensor
FR2609616B1 (fr)	1989-08-18	Oreiller fonctionnel
DK247890D0 (da)	1990-10-12	Gensyntese
PT8062Y (pt)	1992-09-30	Oculos melhorados
KR890700914A (ko)	1989-04-28	멀티콘덴서 배열
DK176389A (da)	1989-10-14	Sonder
KR900014044A (ko)	1990-10-22	활석
FR2613406B1 (fr)	1989-12-29	Boucharde perfectionnee
TR23268A (tr)	1989-08-04	Gizli
FR2635526B1 (fr)	1994-09-02	Derive nucleotidique
ATA192487A (de)	1991-10-15	Sanitaere anordnung
DK505288A (da)	1989-03-12	Makrolidforbindelser
BR8801274A (pt)	1988-10-25	Suporte de lemniscata
ES1001861Y (es)	1989-01-01	Unidad de teclado
ATA153886A (de)	1990-10-15	Ringbuchmechanik
KR900012211U (ko)	1990-07-03	모피 재단용 칼